AstraZeneca Pharmaceuticals LP
NEWS
The Danish pharma giant is partnering with EraCal Therapeutics, to develop new obesity-related drug targets.
Unlike antibody-drug conjugates (ADCs) that focus on antigens, PDCs are able to target the tumor microenvironment that has universal features across solid tumors.
The companies believe the collaboration, valued at more than $1.5 billion, for up to three small molecule therapeutics has the potential to transform oncology treatments.
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
Adagio cited three recent independent, in vitro studies showing that ADG20, which is currently undergoing Phase II/III clinical trials, has neutralization activity against Omicron.
Daiichi wants to maximize its investment in three antibody-drug conjugates, which the company has positioned as one of the strategic pillars of its 5-year Business Plan.
T follicular helper immune cells help antibody-producing cells create increasingly robust antibodies and also enhance the formation of certain types of immune memory.
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
On Friday morning, AstraZeneca’s rare disease group Alexion and Switzerland-based Neurimmune entered into a collaboration and licensing agreement for NI006.
JOBS
IN THE PRESS